SciNeuro Pharmaceuticals, a biotech company pioneering the development of novel treatments for neurodegenerative diseases, today announced the completion of a total of $53 million in equity financing. The round was led by LAV and ARCH Venture Partners with participation from new and existing investors. Together with a $5 million non-dilutive research grant recently awarded by The Michael J. Fox Foundation for Parkinson's Research (MJFF), the proceeds will support the advancement of the company's pipeline of innovative therapeutics targeting a broad range of disease pathways including Lp-PLA21, beta amyloid and LRRK22 as well as the ongoing discovery of novel treatments for other CNS disorders.

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration - neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer's disease, Parkinson's disease, and other devastating CNS diseases.